Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations

Previous studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study was to assess the relation of IGF-I and IGFBP-3 levels with mortality from all causes, cardiovascular disease (CVD), and cancer in a prospect...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The journal of clinical endocrinology and metabolism Ročník 94; číslo 5; s. 1732
Hlavní autori:	Friedrich, Nele, Haring, Robin, Nauck, Matthias, Lüdemann, Jan, Rosskopf, Dieter, Spilcke-Liss, Elisabeth, Felix, Stephan B, Dörr, Marcus, Brabant, Georg, Völzke, Henry, Wallaschofski, Henri
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.05.2009
Predmet:	Adult Aged Cardiovascular Diseases - genetics Cardiovascular Diseases - mortality Female Follow-Up Studies Humans Insulin-Like Growth Factor Binding Protein 3 - blood Insulin-Like Growth Factor Binding Protein 3 - genetics Insulin-Like Growth Factor I - genetics Insulin-Like Growth Factor I - metabolism Male Middle Aged Mortality Neoplasms - genetics Neoplasms - mortality Proportional Hazards Models Socioeconomic Factors Young Adult
ISSN:	1945-7197, 1945-7197
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Previous studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study was to assess the relation of IGF-I and IGFBP-3 levels with mortality from all causes, cardiovascular disease (CVD), and cancer in a prospective population-based study. From the Study of Health in Pomerania (SHIP) 1988 men and 2069 women aged 20-79 yr were followed up on average 8.5 yr. Causes of deaths were coded according to the International Classification of Diseases, 10th revision. Serum IGF-I and IGFBP-3 levels were determined by chemiluminescence immunoassays and categorized into three groups (low, normal, high) according to the sex- and age-specific 10th and 90th percentiles. Adjusted analyses revealed that men with low but not high IGF-I levels had an almost 2-fold higher risk of all-cause mortality [hazard ratio (HR) 1.92 (95% confidence interval [CI] 1.35; 2.73)], CVD mortality [HR 1.92 (95% CI 1.00; 3.71)], and cancer mortality [HR 1.85 (95% CI 1.00; 3.45)] compared with men with normal IGF-I levels. In women, no association between IGF-I and mortality was found. Moreover, low IGFBP-3 levels were associated with higher all-cause mortality in men [HR 1.87 (95% CI 1.31; 2.64)] and women [HR 1.63 (95% CI 0.96; 2.76)]. The present study found inverse associations between IGF-I or IGFBP-3 levels and mortality from all causes, CVD, or cancer in men and between IGFBP-3 and all-cause mortality in women.
AbstractList	Previous studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study was to assess the relation of IGF-I and IGFBP-3 levels with mortality from all causes, cardiovascular disease (CVD), and cancer in a prospective population-based study.BACKGROUNDPrevious studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study was to assess the relation of IGF-I and IGFBP-3 levels with mortality from all causes, cardiovascular disease (CVD), and cancer in a prospective population-based study.From the Study of Health in Pomerania (SHIP) 1988 men and 2069 women aged 20-79 yr were followed up on average 8.5 yr. Causes of deaths were coded according to the International Classification of Diseases, 10th revision. Serum IGF-I and IGFBP-3 levels were determined by chemiluminescence immunoassays and categorized into three groups (low, normal, high) according to the sex- and age-specific 10th and 90th percentiles.METHODSFrom the Study of Health in Pomerania (SHIP) 1988 men and 2069 women aged 20-79 yr were followed up on average 8.5 yr. Causes of deaths were coded according to the International Classification of Diseases, 10th revision. Serum IGF-I and IGFBP-3 levels were determined by chemiluminescence immunoassays and categorized into three groups (low, normal, high) according to the sex- and age-specific 10th and 90th percentiles.Adjusted analyses revealed that men with low but not high IGF-I levels had an almost 2-fold higher risk of all-cause mortality [hazard ratio (HR) 1.92 (95% confidence interval [CI] 1.35; 2.73)], CVD mortality [HR 1.92 (95% CI 1.00; 3.71)], and cancer mortality [HR 1.85 (95% CI 1.00; 3.45)] compared with men with normal IGF-I levels. In women, no association between IGF-I and mortality was found. Moreover, low IGFBP-3 levels were associated with higher all-cause mortality in men [HR 1.87 (95% CI 1.31; 2.64)] and women [HR 1.63 (95% CI 0.96; 2.76)].RESULTSAdjusted analyses revealed that men with low but not high IGF-I levels had an almost 2-fold higher risk of all-cause mortality [hazard ratio (HR) 1.92 (95% confidence interval [CI] 1.35; 2.73)], CVD mortality [HR 1.92 (95% CI 1.00; 3.71)], and cancer mortality [HR 1.85 (95% CI 1.00; 3.45)] compared with men with normal IGF-I levels. In women, no association between IGF-I and mortality was found. Moreover, low IGFBP-3 levels were associated with higher all-cause mortality in men [HR 1.87 (95% CI 1.31; 2.64)] and women [HR 1.63 (95% CI 0.96; 2.76)].The present study found inverse associations between IGF-I or IGFBP-3 levels and mortality from all causes, CVD, or cancer in men and between IGFBP-3 and all-cause mortality in women.CONCLUSIONSThe present study found inverse associations between IGF-I or IGFBP-3 levels and mortality from all causes, CVD, or cancer in men and between IGFBP-3 and all-cause mortality in women. Previous studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study was to assess the relation of IGF-I and IGFBP-3 levels with mortality from all causes, cardiovascular disease (CVD), and cancer in a prospective population-based study. From the Study of Health in Pomerania (SHIP) 1988 men and 2069 women aged 20-79 yr were followed up on average 8.5 yr. Causes of deaths were coded according to the International Classification of Diseases, 10th revision. Serum IGF-I and IGFBP-3 levels were determined by chemiluminescence immunoassays and categorized into three groups (low, normal, high) according to the sex- and age-specific 10th and 90th percentiles. Adjusted analyses revealed that men with low but not high IGF-I levels had an almost 2-fold higher risk of all-cause mortality [hazard ratio (HR) 1.92 (95% confidence interval [CI] 1.35; 2.73)], CVD mortality [HR 1.92 (95% CI 1.00; 3.71)], and cancer mortality [HR 1.85 (95% CI 1.00; 3.45)] compared with men with normal IGF-I levels. In women, no association between IGF-I and mortality was found. Moreover, low IGFBP-3 levels were associated with higher all-cause mortality in men [HR 1.87 (95% CI 1.31; 2.64)] and women [HR 1.63 (95% CI 0.96; 2.76)]. The present study found inverse associations between IGF-I or IGFBP-3 levels and mortality from all causes, CVD, or cancer in men and between IGFBP-3 and all-cause mortality in women.
Author	Friedrich, Nele Brabant, Georg Felix, Stephan B Spilcke-Liss, Elisabeth Völzke, Henry Dörr, Marcus Haring, Robin Rosskopf, Dieter Lüdemann, Jan Nauck, Matthias Wallaschofski, Henri
Author_xml	– sequence: 1 givenname: Nele surname: Friedrich fullname: Friedrich, Nele email: nele.friedrich@uni-greifswald.de organization: Institute for Community Medicine, Ernst Moritz Arndt University, D-17487 Greifswald, Germany. nele.friedrich@uni-greifswald.de – sequence: 2 givenname: Robin surname: Haring fullname: Haring, Robin – sequence: 3 givenname: Matthias surname: Nauck fullname: Nauck, Matthias – sequence: 4 givenname: Jan surname: Lüdemann fullname: Lüdemann, Jan – sequence: 5 givenname: Dieter surname: Rosskopf fullname: Rosskopf, Dieter – sequence: 6 givenname: Elisabeth surname: Spilcke-Liss fullname: Spilcke-Liss, Elisabeth – sequence: 7 givenname: Stephan B surname: Felix fullname: Felix, Stephan B – sequence: 8 givenname: Marcus surname: Dörr fullname: Dörr, Marcus – sequence: 9 givenname: Georg surname: Brabant fullname: Brabant, Georg – sequence: 10 givenname: Henry surname: Völzke fullname: Völzke, Henry – sequence: 11 givenname: Henri surname: Wallaschofski fullname: Wallaschofski, Henri
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/19223521$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtLAzEAhINU7ENvniUn0cPWPHY3m6MUq4WKFz0vedbU3aQmWaT_3qIVPM13-BiGmYKRD94AcInRHBOM7rZqThBqCoJpcwImmJdVwTBno388BtOUtgjhsqzoGRhjTgitCJ6A9jnELDqX91B4DZOJQw-dT0PnfNG5DwM3MXzld2iFyiHCm9Xj8rZY_cgHhNJ57fwG7mLIxnlIoQpeGZ-jyC74dA5OreiSuTjmDLwtH14XT8X65XG1uF8XquSIFLLmTFNrDTXEaGGUELZWWNaIKiotrW2pLVOMV5QLQUxDSsUl0rThUjVakhm4_u09DPkcTMpt75IyXSe8CUNqa0YIQ019EK-O4iB7o9tddL2I-_bvEvIN9sllKA
CitedBy_id	crossref_primary_10_1016_j_ghir_2011_11_001 crossref_primary_10_1038_s41598_018_29193_0 crossref_primary_10_1210_jc_2009_1378 crossref_primary_10_1530_EJE_13_1017 crossref_primary_10_1093_hmg_ddq560 crossref_primary_10_1002_gepi_21766 crossref_primary_10_1177_2047487316661436 crossref_primary_10_1016_j_canep_2010_03_017 crossref_primary_10_1016_j_ghir_2011_02_001 crossref_primary_10_1016_j_ghir_2011_02_003 crossref_primary_10_1586_eem_12_81 crossref_primary_10_3389_fendo_2023_1291812 crossref_primary_10_1016_j_tem_2009_12_005 crossref_primary_10_1093_ije_dyp394 crossref_primary_10_1158_1940_6207_CAPR_19_0375 crossref_primary_10_1111_j_1365_2265_2009_03751_x crossref_primary_10_1161_CIRCULATIONAHA_116_021805 crossref_primary_10_1111_acel_12068 crossref_primary_10_1016_j_hrthm_2019_03_017 crossref_primary_10_2147_PLMI_S447545 crossref_primary_10_1016_j_atherosclerosis_2011_05_034 crossref_primary_10_1530_EJE_09_0247 crossref_primary_10_1016_j_cca_2011_11_015 crossref_primary_10_1371_journal_pone_0251308 crossref_primary_10_2459_JCM_0b013e328358c7c7 crossref_primary_10_1210_jc_2012_2063 crossref_primary_10_1016_j_ghir_2015_09_001 crossref_primary_10_3389_fcvm_2017_00062 crossref_primary_10_1016_j_bcp_2014_12_006 crossref_primary_10_1210_er_2008_0028 crossref_primary_10_1038_s41598_025_94094_y crossref_primary_10_1007_s11523_009_0123_z crossref_primary_10_1155_2021_1219593 crossref_primary_10_1515_CCLM_2010_997 crossref_primary_10_1210_jc_2011_2967 crossref_primary_10_2217_pmt_2021_0042 crossref_primary_10_1542_peds_2009_1783 crossref_primary_10_1371_journal_pone_0214718 crossref_primary_10_3390_cells9061368 crossref_primary_10_1111_acel_13443 crossref_primary_10_1007_s10552_011_9883_8 crossref_primary_10_1016_j_ejim_2016_03_026 crossref_primary_10_1002_dneu_20778 crossref_primary_10_1007_s00103_012_1483_6 crossref_primary_10_1016_S0001_4079_19_31857_6 crossref_primary_10_1111_acel_12490 crossref_primary_10_1016_j_isci_2025_113387 crossref_primary_10_1530_EJE_11_0059 crossref_primary_10_1016_j_ghir_2009_11_004 crossref_primary_10_1210_jc_2013_3746 crossref_primary_10_1016_j_jamda_2013_12_004 crossref_primary_10_1016_j_ghir_2011_09_004 crossref_primary_10_1371_journal_pone_0033084 crossref_primary_10_1016_j_ghir_2010_09_002 crossref_primary_10_1210_er_2012_1002 crossref_primary_10_3390_ijms26157423 crossref_primary_10_1016_j_cmet_2016_05_014 crossref_primary_10_1089_ten_tea_2012_0742 crossref_primary_10_3389_fcvm_2022_863988 crossref_primary_10_1210_jc_2012_2329 crossref_primary_10_1038_s41398_018_0196_5 crossref_primary_10_1111_j_1365_2133_2009_09618_x crossref_primary_10_1186_1471_2369_13_169 crossref_primary_10_1097_HJH_0b013e328364a16d crossref_primary_10_1016_j_ghir_2011_05_004 crossref_primary_10_3390_ijms222111861 crossref_primary_10_1007_s42000_020_00250_6 crossref_primary_10_1007_s11357_018_0042_y crossref_primary_10_1038_ijo_2010_158 crossref_primary_10_1530_EJE_11_0584 crossref_primary_10_1016_j_nut_2014_09_010 crossref_primary_10_1210_jc_2013_3060 crossref_primary_10_1016_j_steroids_2011_10_005 crossref_primary_10_3109_14017431_2014_891760 crossref_primary_10_1007_s40618_022_01819_1 crossref_primary_10_1111_j_1600_051X_2012_01935_x crossref_primary_10_1245_s10434_017_5988_y crossref_primary_10_1111_acel_13540 crossref_primary_10_1111_jgh_14753 crossref_primary_10_1371_journal_pone_0175909 crossref_primary_10_1530_EJE_10_0563 crossref_primary_10_1111_j_1365_2265_2011_04010_x crossref_primary_10_1210_jc_2014_1575
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1210/jc.2008-2138
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1945-7197
ExternalDocumentID	19223521
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 3O- 4.4 48X 53G 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABZA AACZT AAIMJ AAJQQ AAKAS AAPGJ AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYJJ ABBLC ABDFA ABDPE ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABUWG ABVGC ABWST ABXVV ABXZS ACFRR ACGFO ACGFS ACPRK ACUTJ ACVCV ACYHN ACZBC ADBBV ADGKP ADGZP ADHKW ADMTO ADNBA ADQBN ADRTK ADVEK ADZCM AELWJ AEMDU AEMQT AENEX AENZO AEOTA AERZD AETBJ AEWNT AFCHL AFFNX AFFQV AFFZL AFGWE AFKRA AFOFC AFRAH AFXAL AFYAG AGINJ AGKRT AGMDO AGORE AGQXC AGUTN AHGBF AHMBA AHMMS AI. AJBYB AJDVS AJEEA ALMA_UNASSIGNED_HOLDINGS ALXQX APIBT APJGH AQDSO AQKUS ARIXL ASPBG ATGXG AVNTJ AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CCPQU CDBKE CGR CS3 CUY CVF D-I DAKXR DIK E3Z EBS ECM EIF EIHJH EJD EMOBN ENERS F5P FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC GX1 H13 HMCUK HVGLF HZ~ H~9 IAO IHR INH ITC J5H KBUDW KOP KSI KSN L7B M1P M5~ MBLQV MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NPM NU- NVLIB O9- OAUYM OBFPC OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO REU ROX ROZ TEORI TJX TLC TMA TR2 TWZ UKHRP VH1 VVN W8F WHG WOQ X52 X7M YBU YFH YHG YOC YSK ZGI ZXP ZY1 ~02 ~H1 7X8 AEHZK
ID	FETCH-LOGICAL-c4902-b697d3ffe3e2edaecaaf6c1b603c3bf36f4df7c79539aa2e824c9b0d389bc8db2
IEDL.DBID	7X8
ISICitedReferencesCount	104
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00004678-200905000-00042&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1945-7197
IngestDate	Sun Nov 09 11:38:21 EST 2025 Mon Jul 21 05:31:34 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4902-b697d3ffe3e2edaecaaf6c1b603c3bf36f4df7c79539aa2e824c9b0d389bc8db2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	19223521
PQID	67227086
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_67227086 pubmed_primary_19223521
PublicationCentury	2000
PublicationDate	2009-May
PublicationDateYYYYMMDD	2009-05-01
PublicationDate_xml	– month: 05 year: 2009 text: 2009-May
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	The journal of clinical endocrinology and metabolism
PublicationTitleAlternate	J Clin Endocrinol Metab
PublicationYear	2009
SSID	ssj0014453
Score	2.3077524
Snippet	Previous studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1732
SubjectTerms	Adult Aged Cardiovascular Diseases - genetics Cardiovascular Diseases - mortality Female Follow-Up Studies Humans Insulin-Like Growth Factor Binding Protein 3 - blood Insulin-Like Growth Factor Binding Protein 3 - genetics Insulin-Like Growth Factor I - genetics Insulin-Like Growth Factor I - metabolism Male Middle Aged Mortality Neoplasms - genetics Neoplasms - mortality Proportional Hazards Models Socioeconomic Factors Young Adult
Title	Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations
URI	https://www.ncbi.nlm.nih.gov/pubmed/19223521 https://www.proquest.com/docview/67227086
Volume	94
WOSCitedRecordID	wos00004678-200905000-00042&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELYKRYiF96M8PTDAYJHYThxLSAghCh1adQCpW2Q7NpRHWmjL7-fspGJCDCxRhkSyTl_On_PdfYfQqXcYiSJbEJVITSBLJkQ6nRIjjEwlTxxzOgybEL1eNhjIfgNdznthfFnlPCeGRF2MjP9HfpEKSgXw76vxB_Ezo7y2Wg_QWEBNBkTGY1oMfjQEzoMHJZzSEyJiKeqyd9-z8hLMCwEiMct-p5Zhi2mv_W9x62i1ppb4usLCBmrYchMtd2vxfAvl3UC1gXZjVRYYsDd7x3UtOnkbvlr8BGfy6TOuZvDgs85d-5x0wsNwi_UwdMDgYO0wLDHDxvc8lrXx7mQbPbZvH27uST1fgRguIRHqVIqCOWeZpbZQ1ijlUhPrNGKGacdSxwsnjJAJk0pRm1FupI4K4DjaZIWmO2ixHJV2D2EqHGM2SxKVcS5TqrVmLgGqGFHNVWRb6GQeuBzw60UJVdrRbJLPQ9dCu1Xs83Fls5ED96RAD-P9P989QCuVyOPrEA9R08GXa4_QkvmaDiefxwEWcO31u98h9cKM
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mortality+and+serum+insulin-like+growth+factor+%28IGF%29-I+and+IGF+binding+protein+3+concentrations&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Friedrich%2C+Nele&rft.au=Haring%2C+Robin&rft.au=Nauck%2C+Matthias&rft.au=L%C3%BCdemann%2C+Jan&rft.date=2009-05-01&rft.issn=1945-7197&rft.eissn=1945-7197&rft.volume=94&rft.issue=5&rft.spage=1732&rft_id=info:doi/10.1210%2Fjc.2008-2138&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1945-7197&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1945-7197&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1945-7197&client=summon